Tofacitinib has been approved for some various inflammatory and autoimmune diseases. These inflammatory and autoimmune processes play important roles in the pathogenesis of cardiometabolic conditions. so this thesis is trying to show that the effects tofacitinib has as a JAK inhibitor can be beneficial in the treatment of cardiometabolic syndromes.